Published in J Cereb Blood Flow Metab on July 11, 2012
Inflammasomes in the CNS. Nat Rev Neurosci (2014) 1.44
Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis (2013) 1.19
Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci (2012) 1.04
Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem (2014) 0.99
Interleukin-1 and acute brain injury. Front Cell Neurosci (2015) 0.95
Prolonged neuroinflammation after lipopolysaccharide exposure in aged rats. PLoS One (2014) 0.94
Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial. Daru (2013) 0.87
Surgical manipulation compromises leukocyte mobilization responses and inflammation after experimental cerebral ischemia in mice. Front Neurosci (2014) 0.86
Systemic inflammation impairs tissue reperfusion through endothelin-dependent mechanisms in cerebral ischemia. Stroke (2014) 0.85
The role of inflammation and interleukin-1 in acute cerebrovascular disease. J Inflamm Res (2013) 0.84
A cross-laboratory preclinical study on the effectiveness of interleukin-1 receptor antagonist in stroke. J Cereb Blood Flow Metab (2015) 0.83
Aging increases microglial proliferation, delays cell migration, and decreases cortical neurogenesis after focal cerebral ischemia. J Neuroinflammation (2015) 0.81
Simvastatin Reduces Lipopolysaccharides-Accelerated Cerebral Ischemic Injury via Inhibition of Nuclear Factor-kappa B Activity. Biomol Ther (Seoul) (2015) 0.80
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. Expert Rev Neurother (2013) 0.80
Ischemia, Immunosuppression and Infection-Tackling the Predicaments of Post-Stroke Complications. Int J Mol Sci (2016) 0.80
Long-term functional recovery and compensation after cerebral ischemia in rats. Behav Brain Res (2014) 0.79
Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update. Transl Stroke Res (2016) 0.79
Inhibition of inflammatory mediator release from microglia can treat ischemic/hypoxic brain injury. Neural Regen Res (2013) 0.78
Recombinant interleukin-1 receptor antagonist conjugated to superparamagnetic iron oxide nanoparticles for theranostic targeting of experimental glioblastoma. Neoplasia (2015) 0.78
Neuroprotective effect of interleukin-6 in a rat model of cerebral ischemia. Exp Ther Med (2015) 0.78
Knockdown of IL-1β improves hypoxia-ischemia brain associated with IL-6 up-regulation in cell and animal models. Mol Neurobiol (2014) 0.77
Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Antioxid Redox Signal (2014) 0.77
Reparative effects of interleukin-1 receptor antagonist in young and aged/co-morbid rodents after cerebral ischemia. Brain Behav Immun (2016) 0.76
Obesity and stroke: Can we translate from rodents to patients? J Cereb Blood Flow Metab (2016) 0.76
IL-1alpha induces angiogenesis in brain endothelial cells in vitro: implications for brain angiogenesis after acute injury. J Neurochem (2015) 0.76
Requirement for interleukin-1 to drive brain inflammation reveals tissue-specific mechanisms of innate immunity. Eur J Immunol (2014) 0.76
The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia. Curr Pharm Des (2016) 0.75
Intranasal Administration of Interleukin-1 Receptor Antagonist in a Transient Focal Cerebral Ischemia Rat Model. Biomol Ther (Seoul) (2017) 0.75
Anti-inflammatory and neuroprotective effects of sanguinarine following cerebral ischemia in rats. Exp Ther Med (2016) 0.75
Mechanisms of Comorbidities Associated With the Metabolic Syndrome: Insights from the JCR:LA-cp Corpulent Rat Strain. Front Nutr (2016) 0.75
Effect of Septimeb(TM) as a new natural extract on severe sepsis: A randomized clinical trial. Caspian J Intern Med (2017) 0.75
Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke. Int J Mol Sci (2016) 0.75
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke (2009) 6.79
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke (1999) 6.18
RARE imaging: a fast imaging method for clinical MR. Magn Reson Med (1986) 6.17
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature (1990) 5.86
Interleukin-1 and neuronal injury. Nat Rev Immunol (2005) 3.85
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke (2003) 3.18
Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci (2007) 2.47
A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry (2005) 2.41
A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke (1986) 2.34
Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab (2008) 2.33
Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci (2008) 2.21
Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun (2009) 2.13
Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis (2009) 2.12
Systemic infection, inflammation and acute ischemic stroke. Neuroscience (2008) 2.03
Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab (1999) 1.87
Rodent models of cerebral ischemia. Stroke (1989) 1.83
Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab (1996) 1.72
Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans (2007) 1.67
Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun (2003) 1.64
Functional assessments in mice and rats after focal stroke. Neuropharmacology (2000) 1.64
How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost (2009) 1.63
Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol (2003) 1.50
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr Biol (1998) 1.41
Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. J Neurosci (2010) 1.40
Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am J Pathol (1995) 1.28
Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol (1996) 1.28
Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol (1989) 1.25
Temporal profile of T2-weighted MRI distinguishes between pannecrosis and selective neuronal death after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab (2006) 1.23
Role of inflammatory markers in brain ischemia. Curr Opin Neurol (2008) 1.22
A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. J Cereb Blood Flow Metab (2009) 1.22
Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol (2010) 1.10
Early changes in water diffusion, perfusion, T1, and T2 during focal cerebral ischemia in the rat studied at 8.5 T. Magn Reson Med (1999) 1.08
The large and growing burden of stroke. Curr Drug Targets (2007) 1.08
Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab (2009) 1.06
Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia (2006) 1.06
Effect of subacute and chronic immobilisation stress on the outcome of permanent focal cerebral ischaemia in rats. Brain Res (2003) 0.95
Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans (2007) 0.92
Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J Cereb Blood Flow Metab (1997) 0.89
Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and histopathology after middle cerebral artery occlusion. Ann Neurol (1985) 0.86
The role of inflammation in CNS injury and disease. Br J Pharmacol (2006) 3.96
Interleukin-1 and neuronal injury. Nat Rev Immunol (2005) 3.85
Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell (2005) 2.63
Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci (2007) 2.47
Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol (2004) 2.30
Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci (2008) 2.21
Invasive rodent eradication on islands. Conserv Biol (2007) 2.03
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol (2003) 1.97
Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes (2010) 1.97
Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J Cell Sci (2007) 1.80
Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab (2007) 1.71
CNS injury: the role of the cytokine IL-1. Vet J (2004) 1.65
Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol (2006) 1.63
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome. Endocrinology (2009) 1.60
Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci (2003) 1.56
Skeletal parasympathetic innervation communicates central IL-1 signals regulating bone mass accrual. Proc Natl Acad Sci U S A (2012) 1.56
Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J Biol Chem (2001) 1.52
Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr (2006) 1.51
Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol (2003) 1.50
Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity. J Biol Chem (2010) 1.44
Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun (2011) 1.44
Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr (2002) 1.42
Ca2+ stores and Ca2+ entry differentially contribute to the release of IL-1 beta and IL-1 alpha from murine macrophages. J Immunol (2003) 1.39
Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood (2010) 1.38
Inflammation in human brain injury: intracerebral concentrations of IL-1alpha, IL-1beta, and their endogenous inhibitor IL-1ra. J Neurotrauma (2007) 1.36
Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab (2007) 1.34
NLRP3-Inflammasome Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of Priming Which Contributes to Brain Inflammation after Injury. Front Immunol (2012) 1.33
Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J Neurochem (2006) 1.27
A rapid and transient peripheral inflammatory response precedes brain inflammation after experimental stroke. J Cereb Blood Flow Metab (2009) 1.22
Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem (2007) 1.20
Effects of ruminant trans fatty acids on cardiovascular disease and cancer: a comprehensive review of epidemiological, clinical, and mechanistic studies. Adv Nutr (2011) 1.18
Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis (2011) 1.18
Random tiling and topological defects in a two-dimensional molecular network. Science (2008) 1.17
A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol (2003) 1.17
Regulation of interleukin-1 in acute brain injury. Trends Pharmacol Sci (2011) 1.15
Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci (2003) 1.14
Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation (2011) 1.12
Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol (2007) 1.12
Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans (2011) 1.12
Targeted deletion of the mitogen-activated protein kinase kinase 4 gene in the nervous system causes severe brain developmental defects and premature death. Mol Cell Biol (2007) 1.11
Hypoxia-induced intrauterine growth restriction increases the susceptibility of rats to high-fat diet-induced metabolic syndrome. Diabetes (2011) 1.11
Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia. Hepatology (2012) 1.10
Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol (2012) 1.10
Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol (2010) 1.10
Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem (2002) 1.09
Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci (2002) 1.09
Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Dis Model Mech (2012) 1.09
Experimental stroke-induced changes in the bone marrow reveal complex regulation of leukocyte responses. J Cereb Blood Flow Metab (2010) 1.08
MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2013) 1.06
Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab (2009) 1.06
Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res (2002) 1.06
Role of P2X7 receptors in ischemic and excitotoxic brain injury in vivo. J Cereb Blood Flow Metab (2003) 1.06
Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia (2006) 1.06
Microglia and macrophages differentially modulate cell death after brain injury caused by oxygen-glucose deprivation in organotypic brain slices. Glia (2013) 1.05
Guest-induced growth of a surface-based supramolecular bilayer. Nat Chem (2010) 1.05
Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med (2011) 1.03
Neuronal Toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. J Neuroinflammation (2012) 1.02
Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol (2007) 1.02
Experimental intracerebral hemorrhage: avoiding pitfalls in translational research. J Cereb Blood Flow Metab (2011) 1.02
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One (2013) 1.00
Regulation of postnatal forebrain amoeboid microglial cell proliferation and development by the transcription factor Runx1. J Neurosci (2012) 1.00
Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol Cell Neurosci (2002) 1.00
Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol Cell Neurosci (2007) 0.98
Integrin-binding RGD peptides induce rapid intracellular calcium increases and MAPK signaling in cortical neurons. Mol Cell Neurosci (2006) 0.98
Glucose tolerance, lipids, and GLP-1 secretion in JCR:LA-cp rats fed a high protein fiber diet. Obesity (Silver Spring) (2008) 0.97
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing. Nat Chem Biol (2011) 0.97
Chronic dietary n-3 PUFA intervention improves dyslipidaemia and subsequent cardiovascular complications in the JCR:LA- cp rat model of the metabolic syndrome. Br J Nutr (2011) 0.97
Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab (2002) 0.96
The immune system in stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol (2013) 0.96